长春新碱抗肿瘤新剂型的研究进展

Research progress on anti-tumor novel drug delivery system of vincristine

长春新碱作为临床一线广谱化疗药物广泛用于实体瘤的治疗,由于存在药物半衰期短、神经系统和胃肠道毒性强等缺点,使其临床应用受到限制。因此,提高长春新碱的肿瘤靶向性、延长体内滞留时间,将其制备成新型给药系统具有重要意义。近十年来国内外关于长春新碱的新剂型研究主要有纳米粒、脂质体、微泡、微球等,这些新剂型提高了长春新碱生物利用度,使其具有良好的缓控释能力或肿瘤靶向能力。针对长春新碱抗肿瘤新型给药系统的研究做一综述,为合理开发长春新碱新剂型提供理论依据。

Vincristine is widely used in the treatment of solid tumors as a clinical first-line broad-spectrum chemotherapy drug.However, its clinical application is limited due to some shortcomings, such as short half-life, rapid elimination, strong toxicity of nervous system and gastrointestinal tract. Therefore, it is of great significance to prepare vincristine into a new drug delivery system to improve the tumor targeting of vincristine and prolong the retention time in vivo. The research on new drug delivery system of vincristine in recent ten years is reviewed, including nanoparticles, liposomes, microvesicle and microspheres, which had improved the bioavailability of vincristine and made it good controlled release ability or tumor targeting ability, and the research on new drug delivery system of vincristine is reviewed to provide theoretical basis for the rational development of new formulations of vincristine.